Organ Preservation Market - Future Growth Prospects for the Global Key Players

 Global Leading Companies:

The global organ preservation market is less fragmented and highly competitive.

Some of the major players governing the overall organ preservation market include Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), and Global Transplant Solutions (US).

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=261269915

Paragonix Technologies (US) is the leading market player for their organ preservation and transport devices. It operates mainly in the US and Europe. The company is focused in developments such as new product launches, partnerships, agreements and approvals since 2016. The company has developed devices for all major thoracic and abdominal organ preservation and transport. Paragonix also focuses on software services and tools for real-time organ tracking.

The company recently launched a new organ transport device Sherpapak Pancreas Transport System. Paragonix also partnered with Lung Transplant Foundation to develop a series of technologies to improve donor lung preservation. In January 2021, the company partnered with Southwest Transplant Alliance (STA) to provide advanced organ preservation technologies. Such development proves the strong market prevalence of the company.

XVIVO Perfusion AB (Sweden) is a prominent player in the market and a public domain company. It is headquartered in Sweden and conducts operations in Europe, Asia, the Middle East, and North & South America. It spends nearly 31% of its revenue on R&D as a result of which the company is involved in developing improved products for organ perfusion.

XVIVO’s lung perfusion solution is used mainly in Lung Preservation, making the solution a gold standard for lung preservation. In September 2020, XVIVO Perfusion entered into an acquisition agreement with Organ Assist. This agreement further strengthened the company’s product offerings and expanded its addressable market.

Dr. Franz Kohler Chemie GMBH (Germany) is another market leader of organ preservation solutions since 1959. It is involved in the development of electrolyte solutions, organ-protective solutions, therapeutics, antidotes, and X-ray contrast agents and medical devices. It has captured the market for Custodial, an organ preservation solution.

Custodial holds advantages over other solutions like reduced viscosity and an improved graft survival rate and is widely used for the preservation of all organs unlike other solutions. Due to these advantages of a Custodial solution for organ preservation, it proves that Dr. Franz Kohler Chemie GMBH holds a substantial market prevalence.

Asia-Pacific is expected to register the highest CAGR in the organ preservation market

The Asia-Pacific market is expected to grow at the highest CAGR from 2021 to 2026. This can be attributed to factors such as the favorable government initiatives, increased awareness in people and increased organ donations. The universal government regulations in China and Japan (including for transplantation & related organ donation procedures), expanding healthcare infrastructures, increasing prevalence of chronic diseases, and growing medical tourism in RoAPAC countries will contribute to market growth in the APAC.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=261269915